ASMS 2024

The Metabolon team is excited to announce their participation in the upcoming American Society for Mass Spectrometry (ASMS) conference, scheduled to take place June 2-6 in Anaheim, California. They will be presenting two posters and an oral presentation that showcase their latest advancements and research findings in the field of metabolomics. These posters will highlight Metabolon’s innovative approaches and technological developments in mass spectrometry, offering insights into how their work is pushing the boundaries of metabolite detection and analysis.

The team looks forward to engaging with fellow scientists and industry professionals, discussing their cutting-edge research, and exploring new collaborations to further enhance the understanding and application of metabolomics in various scientific disciplines.

For more event information, you can read visit the official event website or read the official program.

Take a look back: view information for Metabolon’s attendance at ASMS 2023.

Oral Presentation

Harnessing the Mass Spectrometer for Effortless Transition within the Biomarker Pipeline
Thermo Fisher Annual User Meeting – Metabolomics Breakout: Metabolites, Lipids, and MultiOmic Methods
Sunday June 2nd, 2024

Abstract:
The Core Research team at Metabolon is dedicated to identifying cutting-edge technologies that can transform our analysis and understanding of biological systems. These presentations at the ThermoFisher Annual Users Meeting will showcase our experiences and insights gained from evaluating the latest ThermoFisher instrumentation, set to debut this year at the ASMS conference in Anaheim, California. In particular, we will emphasize how this new instrument facilitates seamless translatability throughout the biomarker pipeline, enabling rapid analytical development from untargeted to targeted metabolomics.

Poster Presentation

Evaluation of Tissues Preserved in RNAlater for Metabolomics Analysis.
Monday, June 3rd, 2024

Abstract:
Multi-omic analyses allow for a holistic and comprehensive understanding of biology assisting in the identification and elucidation of biomarkers. As the need for multi-omic analyses increases, there is a desire to develop biologically relevant metabolomic data from samples previously collected and stabilized for genomics and transcriptomics. RNAlater aims to stabilize cellular RNA by permeation into tissues, cells, and fecal samples enabling temporary storage at room temperature and alleviating the immediate need for sample processing and freezing. RNAlater stabilizes RNA by denaturing macromolecular enzymes such as DNase, RNase, and Proteases making it suitable for genomic, transcriptomic, and proteomics analyses. Historically, macromolecular stabilization buffers have been problematic in metabolomic analysis for a variety of reasons including ionization suppression and instrument contamination from highly abundant buffer components. This work aims to investigate the effects of sample storage in RNAlater on Metabolon’s Global Discovery Panel (untargeted metabolomics). A biological case study was simulated between adult and calf liver to investigate if biological signatures were maintained between fresh frozen and RNAlater treated samples. Additionally, RNAlater samples were evaluated for reproducibility, sensitivity, biochemical coverage, pathway coverage, and instrument contamination and carryover.

Poster Presentation

Validation of Targeted Quantitative Analysis of Endogenous Biomarkers for Good Clinical Practice Studies.
Wednesday, June 5th, 2024

Abstract:
Metabolon, Inc. develops and validates absolute quantitation analytical methods to measure metabolites that are biologically significant for identifying the presence of disease or other conditions. When pharmaceutical companies want to study the effect of a novel treatment for a disease in patients, it is important that supporting data follows Good Clinical Practice (GCP) requirements. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) released the M10 Bioanalytical Method Validation and Study Sample Analysis Guidance for Industry (M10) in November 2022 as a harmonization of the regulatory expectations for clinical studies across the world. The standards help to ensure safe, effective, and high-quality medicines are developed for patients. The guidance lacks application to endogenous biomarker analysis, and there is no alternative guidance published. Metabolon, Inc., utilized the M10 guidance to prepare standard operating procedures for bioanalytical method validation of endogenous biomarkers for studies that are subject to GCP requirements.